Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CTMX

CTMX - CytomX Therapeutics Inc Stock Price, Fair Value and News

$4.68-0.19 (-3.90%)
Market Closed

42/100

CTMX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

42/100

CTMX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CTMX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CTMX Price Action

Last 30 days

-15.8%

Last 90 days

11.7%

Trailing 12 Months

693.2%

CTMX RSI Chart

CTMX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CTMX Valuation

Market Cap

793.0M

Price/Earnings (Trailing)

28.3

Price/Sales (Trailing)

6.98

EV/EBITDA

26.85

Price/Free Cashflow

-10.96

CTMX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CTMX Fundamentals

CTMX Revenue

Revenue (TTM)

113.6M

Rev. Growth (Yr)

-82.16%

Rev. Growth (Qtr)

-68.04%

CTMX Earnings

Earnings (TTM)

28.0M

Earnings Growth (Yr)

-348.06%

Earnings Growth (Qtr)

-9.1K%

CTMX Profitability

EBT Margin

24.87%

Return on Equity

26.09%

Return on Assets

17.7%

Free Cashflow Yield

-9.12%

CTMX Investor Care

Shares Dilution (1Y)

116.51%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025147.6M141.1M113.6M0
2024119.2M119.6M126.6M138.1M
202367.6M79.5M94.7M101.2M
202238.2M42.2M44.2M53.2M
202129.7M31.5M33.3M37.3M
202074.9M72.9M69.6M68.4M
201974.8M62.5M60.7M57.5M
201874.2M86.7M75.1M59.5M
201724.5M30.1M50.8M71.6M
20168.2M9.2M10.8M15.0M
20156.2M7.6M7.6M7.7M
20141.9M3.0M4.0M5.1M
2013000888.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About CytomX Therapeutics Inc

CTMX
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; CX-2051, a conditionally activated ADC that targets epithelial cell adhesion molecule-expressing epithelial cancers; and CX-801, a dually masked, conditionally activated version of Interferon alpha-2b therapy for a range of tumor types. The company also develops BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I/II clinical trials for the treatment of solid tumors; and CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. It has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, Astellas Pharma Inc., ModernaTX, Inc., and Regeneron Pharmaceuticals, Inc. The company was founded in 2008 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEcytomx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES116

CytomX Therapeutics Inc Frequently Asked Questions

CTMX is the stock ticker symbol of CytomX Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of CytomX Therapeutics Inc is 792.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, CTMX's PE ratio (Price to Earnings) is 28.3 and Price to Sales (PS) ratio is 6.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CTMX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, CytomX Therapeutics Inc has provided -0.096 (multiply by 100 for percentage) rate of return.